Literature DB >> 9741433

A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.

E M Jaffee1, R Abrams, J Cameron, R Donehower, M Duerr, J Gossett, T F Greten, L Grochow, R Hruban, S Kern, K D Lillemoe, S O'Reilly, D Pardoll, H A Pitt, P Sauter, C Weber, C Yeo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9741433     DOI： 10.1089/hum.1998.9.13-1951

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  12 in total

Review 1.  Adjuvant therapy for pancreatic adenocarcinoma.

Authors:  R A Abrams
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

2.  Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Authors:  Jack C F Liao; Polly Gregor; Jedd D Wolchok; Francesca Orlandi; Diane Craft; Carrie Leung; Alan N Houghton; Philip J Bergman
Journal:  Cancer Immun       Date:  2006-04-21

3.  Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.

Authors:  S M Todryk; L J Birchall; R Erlich; N Halanek; J K Orleans-Lindsay; A G Dalgleish
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

4.  Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome.

Authors:  C J Yeo; J L Cameron; T A Sohn; J Coleman; P K Sauter; R H Hruban; H A Pitt; K D Lillemoe
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

Review 5.  The potential for gene therapy in pancreatic cancer.

Authors:  M J Humphreys; W Greenhalf; J P Neoptolemos; P Ghaneh
Journal:  Int J Pancreatol       Date:  1999-08

6.  A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.

Authors:  Eric Lutz; Charles J Yeo; Keith D Lillemoe; Barbara Biedrzycki; Barry Kobrin; Joseph Herman; Elizabeth Sugar; Steven Piantadosi; John L Cameron; Sara Solt; Beth Onners; Irena Tartakovsky; Miri Choi; Rajni Sharma; Peter B Illei; Ralph H Hruban; Ross A Abrams; Dung Le; Elizabeth Jaffee; Dan Laheru
Journal:  Ann Surg       Date:  2011-02       Impact factor: 12.969

7.  Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.

Authors:  Dan Laheru; Barbara Biedrzycki; Elizabeth M Jaffee
Journal:  Methods Mol Biol       Date:  2013

8.  Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

Authors:  Alessandra De Remigis; Tanja D de Gruijl; Jennifer N Uram; Schey-Cherng Tzou; Shintaro Iwama; Monica V Talor; Todd D Armstrong; Saskia J A M Santegoets; Susan F Slovin; Lei Zheng; Daniel A Laheru; Elizabeth M Jaffee; Winald R Gerritsen; Alfons J M van den Eertwegh; Dung T Le; Patrizio Caturegli
Journal:  Int J Cancer       Date:  2014-05-28       Impact factor: 7.396

9.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Authors:  Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

Review 10.  Developing recombinant and synthetic vaccines for the treatment of melanoma.

Authors:  N P Restifo; S A Rosenberg
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.